BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 30689031)

  • 21. Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients.
    Dimitrakopoulou-Strauss A; Strauss L
    Hell J Nucl Med; 2006; 9(1):10-21. PubMed ID: 16617388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Whole-body direct 4D parametric PET imaging employing nested generalized Patlak expectation-maximization reconstruction.
    Karakatsanis NA; Casey ME; Lodge MA; Rahmim A; Zaidi H
    Phys Med Biol; 2016 Aug; 61(15):5456-85. PubMed ID: 27383991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dynamic whole-body PET parametric imaging: II. Task-oriented statistical estimation.
    Karakatsanis NA; Lodge MA; Zhou Y; Wahl RL; Rahmim A
    Phys Med Biol; 2013 Oct; 58(20):7419-45. PubMed ID: 24080994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamic whole-body PET parametric imaging: I. Concept, acquisition protocol optimization and clinical application.
    Karakatsanis NA; Lodge MA; Tahari AK; Zhou Y; Wahl RL; Rahmim A
    Phys Med Biol; 2013 Oct; 58(20):7391-418. PubMed ID: 24080962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of dynamic and parametric whole-body FDG PET/CT imaging in molecular characterization of primary breast cancer: a single institution experience.
    Sundaraiya S; T R; Nangia S; Sirohi B; Patil S
    Nucl Med Commun; 2022 Sep; 43(9):1015-1025. PubMed ID: 35950356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
    Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
    J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Tumor Uptake Heterogeneity Characterization Between Static and Parametric 18F-FDG PET Images in Non-Small Cell Lung Cancer.
    Tixier F; Vriens D; Cheze-Le Rest C; Hatt M; Disselhorst JA; Oyen WJ; de Geus-Oei LF; Visser EP; Visvikis D
    J Nucl Med; 2016 Jul; 57(7):1033-9. PubMed ID: 26966161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative Performance of ¹⁸F-FDG PET/MRI and ¹⁸F-FDG PET/CT in Detection and Characterization of Pulmonary Lesions in 121 Oncologic Patients.
    Sawicki LM; Grueneisen J; Buchbender C; Schaarschmidt BM; Gomez B; Ruhlmann V; Wetter A; Umutlu L; Antoch G; Heusch P
    J Nucl Med; 2016 Apr; 57(4):582-6. PubMed ID: 26742715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of pulmonary lesions with low F-18 FDG uptake using double phase F-18 FDG PET/CT: comparison of visual and quantitative analyses.
    Kim IJ; Kim SJ; Kim YS; Lee TH; Jeong YJ
    Neoplasma; 2009; 56(1):33-9. PubMed ID: 19152243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Standardized uptake values for [¹⁸F] FDG in normal organ tissues: comparison of whole-body PET/CT and PET/MRI.
    Heusch P; Buchbender C; Beiderwellen K; Nensa F; Hartung-Knemeyer V; Lauenstein TC; Bockisch A; Forsting M; Antoch G; Heusner TA
    Eur J Radiol; 2013 May; 82(5):870-6. PubMed ID: 23394765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generation of parametric K
    Wu J; Liu H; Ye Q; Gallezot JD; Naganawa M; Miao T; Lu Y; Chen MK; Esserman DA; Kyriakides TC; Carson RE; Liu C
    Med Phys; 2021 Sep; 48(9):5219-5231. PubMed ID: 34287939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual-time-point 18F-FDG PET for the evaluation of gallbladder carcinoma.
    Nishiyama Y; Yamamoto Y; Fukunaga K; Kimura N; Miki A; Sasakawa Y; Wakabayashi H; Satoh K; Ohkawa M
    J Nucl Med; 2006 Apr; 47(4):633-8. PubMed ID: 16595497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
    Metser U; Even-Sapir E
    Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incremental Value of 18 F-FDG-Labeled Leukocytes PET/CT Over 18 F-FDG PET/CT Scan in the Detection of Occult Infection.
    Manda D; Thakral P; Sen I; Das SS; Cb V; Malik D
    Clin Nucl Med; 2022 Sep; 47(9):e574-e581. PubMed ID: 35776834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial.
    Zanoni L; Broccoli A; Lambertini A; Pellegrini C; Stefoni V; Lodi F; Fonti C; Nanni C; Zinzani PL; Fanti S
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1661-1671. PubMed ID: 31102000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization.
    Choi JY; Lee KS; Kim HJ; Shim YM; Kwon OJ; Park K; Baek CH; Chung JH; Lee KH; Kim BT
    J Nucl Med; 2006 Apr; 47(4):609-15. PubMed ID: 16595494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative evaluation of skeletal tumours with dynamic FDG PET: SUV in comparison to Patlak analysis.
    Wu H; Dimitrakopoulou-Strauss A; Heichel TO; Lehner B; Bernd L; Ewerbeck V; Burger C; Strauss LG
    Eur J Nucl Med; 2001 Jun; 28(6):704-10. PubMed ID: 11440030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic usefulness of FDG PET for pancreatic mass lesions.
    Koyama K; Okamura T; Kawabe J; Nakata B; Chung KH; Ochi H; Yamada R
    Ann Nucl Med; 2001 Jun; 15(3):217-24. PubMed ID: 11545191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.